Renal cell carcinoma · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	surveillance
Linked regimen	`None`

ID	`IND-VHL-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-RCC`
Sources	`SRC-ESMO-RCC-2024` `SRC-NCCN-KIDNEY-2025`

Notes

STUB — alternative-track companion for VHL hereditary prevention pilot. §15.2 C4 ≥2-tracks invariant compliance.

Used By

Algorithms

ALGO-CASCADE-FAMILY-TESTING - ALGO-CASCADE-FAMILY-TESTING
ALGO-INTEGRATED-RISK-FROM-MULTIPLE-RFS - ALGO-INTEGRATED-RISK-FROM-MULTIPLE-RFS
ALGO-MULTI-SYNDROME-PEDIGREE-TRIAGE - ALGO-MULTI-SYNDROME-PEDIGREE-TRIAGE
ALGO-PEDIATRIC-CANCER-PREDISPOSITION-TRIAGE - ALGO-PEDIATRIC-CANCER-PREDISPOSITION-TRIAGE
ALGO-PREVENTION-RISK-TRIAGE-OVERVIEW - ALGO-PREVENTION-RISK-TRIAGE-OVERVIEW
ALGO-VHL-CARRIER-SURVEILLANCE-VHL-ALLIANCE - ALGO-VHL-CARRIER-SURVEILLANCE-VHL-ALLIANCE